MOLN Presents MP0712 Phase 1/2a Trial Updates at ASCO and SNMMI 2026, Dosing Patients with DLL3-Targeting Radio-DARPin Therapy
Molecular Partners AG American Depositary Shares · Now $3.95
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS